Dr. Denduluri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1635 N George Mason Dr
Ste 170
Arlington, VA 22205Phone+1 703-528-7303Fax+1 703-528-0338
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2003 - 2007
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1999 - 2002
LSU School of Medicine in ShreveportClass of 1999
Certifications & Licensure
VA State Medical License 1999 - 2026
DC State Medical License 2001 - 2013
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer Start of enrollment: 2006 Jan 01
- Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
- A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsDatopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Brea...Aditya Bardia, Komal Jhaveri, Seock-Ah Im, Sonia Pernas, Michelino De Laurentiis
Journal of Clinical Oncology. 2025-01-20 - Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones
Nature Communications. 2024-05-10 - 3 citationsAdjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones
Nature Communications. 2024-03-27
Press Mentions
The Ongoing Challenge of Pandemic Fatigue Is Hitting People HardJanuary 13th, 2021- Cardiotoxicity in Cancer Tx: LVEF Less Than 55% Is PredictiveJune 17th, 2020
11 Symptoms of Breast Cancer in Women That Aren’t LumpsSeptember 24th, 2019- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
